NDAORALTABLET
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
GLYXAMBI (empagliflozin and linagliptin) by Boehringer Ingelheim is sodium-glucose transporter 2 inhibitors [moa]. Approved for sodium-glucose cotransporter 2 inhibitor [epc]. First approved in 2015.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GLYXAMBI is an oral fixed-dose combination tablet containing empagliflozin (a sodium-glucose cotransporter 2 inhibitor) and linagliptin (a dipeptidyl peptidase-4 inhibitor) approved by the FDA on January 30, 2015. It is indicated for the treatment of type 2 diabetes mellitus to improve glycemic control. The combination works through dual mechanisms: empagliflozin increases urinary glucose excretion while linagliptin enhances insulin secretion by inhibiting DPP-4. GLYXAMBI positions itself as a comprehensive dual-agent therapy in a crowded antidiabetic market dominated by Boehringer Ingelheim's own empagliflozin monotherapy franchise.
$0.1BPart D
11.6 years to LOEMechanism of Action
Sodium-Glucose Transporter 2 Inhibitors
Pharmacologic Class:
Sodium-Glucose Cotransporter 2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
Started Feb 2013
607 enrolled
Diabetes Mellitus, Type 2
Why This Matters for Your Career
Worked on GLYXAMBI at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.